HARP News and Press, Harpoon Therapeutics Inc. From 01/06/21

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that th...

Gainers: [[SOS]] +63.9%. [[XNET]] +23.7%. [[TEN]] +11.2%. [[CERS]] +8.9%. [[SITM]] +8.3%.Losers: [[GBTC]] -8.9%. [[PLYA]] -7.5%. [[UUU]] -6.5%. [[INN]] -6.4%. [[HARP]] -5.8%. For further details see: SOS, XNET, UUU and PLYA among after-hours movers

Harpoon Therapeutics (HARP) commences an underwritten public offering of its common stock.Underwriters option to purchase up to an additional 15% of the number of shares sold.Net proceeds of the offering, together with other available funds, to fund the continued clinical development of ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock. In connect...

Harpoon Therapeutics (HARP) has dosed the first patient with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer ((SCLC)) and other tumors associated with DLL3 expression.The trial plans to enroll pati...

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targ...

Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP’s most advanced product, targets prostate cancer, which alone presents an opportunity of over $5 billion. HARP’s attraction, a...

Harpoon Therapeutics ([[HARP]] +3.7%) has reported a confirmed partial response for its most advanced program, HPN424 in Phase 1/2a study for the treatment of metastatic castration-resistant prostate cancer.At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 showed c...

HPN424 has show n confir med partial response in treatment of metastatic castration - resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1 /2a d o se escalation trial Thre...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will host a conference call and webcast to review the status and provide a cl...